| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/05/2008 | US20080132538 Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
| 06/05/2008 | US20080132537 Viricides; antiinflammatory agents; infection therapy; respiratory system disorders |
| 06/05/2008 | US20080132536 treatment or prophylaxis of inflammatory or allergic diseases chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis; 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide |
| 06/05/2008 | US20080132535 for buccal delivery; carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5 irrespective of starting pH; treating middle-of-the-night insomnia |
| 06/05/2008 | US20080132534 Pharmaceutical composition comprising a macrolide immunomodulator |
| 06/05/2008 | US20080132533 Solid Dispersion Comprising Tacrolimus and Entericcoated Macromolecule |
| 06/05/2008 | US20080132532 dosage strength of the second dosage form is greater than that of the first dosage form; kits |
| 06/05/2008 | US20080132531 Synergistic combinations of norketamine and opioid analgesics |
| 06/05/2008 | US20080132530 polymorphic forms alpha , beta and gamma; for the oral or topical route; In case of invasive bacteria, it may be useful to use the most bioavailable polymorphic form, whereas in case of non-invasive pathogens it may be more appropriate to use the less adsorbed forms, since they are safer |
| 06/05/2008 | US20080132529 Method of improving bioavailability for non-sedating barbiturates |
| 06/05/2008 | US20080132528 Kinase inhibitors and methods for using the same |
| 06/05/2008 | US20080132527 Compositions For Delivering Acyclovir |
| 06/05/2008 | US20080132526 Purine Derivative |
| 06/05/2008 | US20080132525 isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid |
| 06/05/2008 | US20080132523 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 06/05/2008 | US20080132521 Isoquinolinone Derivatives and Their Use As Therapeutic Agents |
| 06/05/2008 | US20080132520 Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds |
| 06/05/2008 | US20080132519 nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels |
| 06/05/2008 | US20080132518 novel polymorphic forms of aripiprazole in the treatment of schizophrenia; properties suitable for pharmaceutical processing on a commercial scale |
| 06/05/2008 | US20080132517 Method of enhancing absorptions of transmucosal administration formulations |
| 06/05/2008 | US20080132516 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS |
| 06/05/2008 | US20080132515 Substituted Azaquinazolines Having an Antiviral Action |
| 06/05/2008 | US20080132514 bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity |
| 06/05/2008 | US20080132513 new mechanism of action, oral bioavailability and/or reduced side effects; Ca2+-release-activated Ca2+ channels inhibitors; IL-2, IL-4, IL-5, IL-13, GM-CSF, TNF- alpha , and IFN gamma inhibitors; immunosuppressant |
| 06/05/2008 | US20080132512 Combination of Brimonidine and Timolol for Topical Ophthalmic Use |
| 06/05/2008 | US20080132511 Sulfonamide compounds |
| 06/05/2008 | US20080132510 to modulate ligand binding to GABAA receptors; treatment of central nervous system (CNS) disorders; anxiety, depression, a sleep disorder, attention deficit disorder, Alzheimer's dementia or short-term memory loss |
| 06/05/2008 | US20080132509 vanilloid receptor antagonist; capsaicin receptor modulators; as probes for the detection and localization of capsaicin receptors; to treat pain or to reduce calcium conductance of a cellular capsaicin receptor; 5'-[6-(3-chloro-4-fluorophenyl)-2-morpholin-4-ylpyrimidin-4-yl]-3-methyl-2,2'-bipyridine |
| 06/05/2008 | US20080132508 compound that inhibits glycosphingolipid synthesis; includes PPMP, PDMP, or NB-DGJ or any derivative or analog thereof or any derivative of ceramide that inhibits glycosphingolipid metabolism |
| 06/05/2008 | US20080132507 Hydrazide Derivatives |
| 06/05/2008 | US20080132506 Anti-inflammatory medicaments |
| 06/05/2008 | US20080132505 Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine |
| 06/05/2008 | US20080132504 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders |
| 06/05/2008 | US20080132503 Inhibitors of Histone Deacetylase |
| 06/05/2008 | US20080132502 Phosphatidylinositol (PI) 3-kinase (PI3K); N-[5-(5-Benzylamino-6-chloropyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide, for example; anticancer agents, cardiovascular disorders, autoimmune disorders, rheumatic diseases |
| 06/05/2008 | US20080132501 Indazole compounds |
| 06/05/2008 | US20080132500 Antibiotic compounds |
| 06/05/2008 | US20080132499 Platelet adp receptor inhibitors |
| 06/05/2008 | US20080132497 Novel Heterocycles |
| 06/05/2008 | US20080132496 Anticoagulants; factor Xa inhibitors; compounds are N-(benzimidazolyl, imidazo(4,5-b)pyridyl- or indolyl)-substituted benzamides |
| 06/05/2008 | US20080132495 Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases |
| 06/05/2008 | US20080132494 Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| 06/05/2008 | US20080132493 Aqueous cyclodextrin-free solution; analgesics, antiinflammatories, antipyretics |
| 06/05/2008 | US20080132492 Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency |
| 06/05/2008 | US20080132491 Indazole-carboxamide compounds |
| 06/05/2008 | US20080132490 1-heteroaryl-4-benzoyl-5-(alkyl or cycloalkyl)-1,4-diazepanes; sleep disorders, analgesics, obesity, Parkinson's disease, psychosis and schizophrenia; 6-fluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinazoline for example |
| 06/05/2008 | US20080132489 1-aryl-alkyl-substituted-1,4-diazepine derivatives; 1-(4-Chloro-3-methoxy-phenyl)-3,3,5,5-tetramethyl-[1,4]diazepane for example; antidepressants, analgesics, various psychological disorders, dementia, eating disorders, drug abuse; side effect reduction |
| 06/05/2008 | US20080132488 Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke |
| 06/05/2008 | US20080132487 5-aminopyrazole derivatives as pesticidal compounds |
| 06/05/2008 | US20080132486 Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them |
| 06/05/2008 | US20080132485 Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis |
| 06/05/2008 | US20080132484 Screening for a modulator of Polio Like Kinase, designing and identifying small molecule inhibitors using a homology model for PLK |
| 06/05/2008 | US20080132483 Administering (3R,5S)-N-propanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide; cerebral infarction |
| 06/05/2008 | US20080132482 3-(2(R)-Cyclopentylmethyl-3 (S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one; neurological disorders related to beta -amyloid production, Alzheimer's disease, Down's Syndrome |
| 06/05/2008 | US20080132481 Use of 3-substituted amino-2-carboxy-substituted indoles or benzo(b)thiophenes or esters thereof that modulate T helper (Th) cells; treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections |
| 06/05/2008 | US20080132480 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease |
| 06/05/2008 | US20080132479 Oxime Derivative and Preparations Thereof |
| 06/05/2008 | US20080132478 Modified release amoxicillin products |
| 06/05/2008 | US20080132477 BACE (beta-site APP-cleaving enzyme) or Cathepsin D, close homologues of beta-secretase; treating neurodegenerative diseases such as Alzheimer's; macrocyclic amides having ring sizes of 14-17 and fused 1,3-phenylene optionally with 2,4-pyridylene groups |
| 06/05/2008 | US20080132476 Administering e.g. 17beta-Fluoro-9alpha-vinyl-estra-1,3,5(10)-triene-3,16alpha-diol to treat endometriosis, osteoporosis, or hormone replacement therapy in combination with other drugs |
| 06/05/2008 | US20080132475 Progestagen as progesterone, a derivative of progesterone, synthetic progestagen, medroxyprogesterone acetate, norethindrone, norethindrone acetate, megestrol acetate, 17-a-hydroxyprogesterone caproate or norgestrel |
| 06/05/2008 | US20080132474 Breast cancer screening and treatment methods |
| 06/05/2008 | US20080132473 Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology |
| 06/05/2008 | US20080132472 Compounds for the treatment of psychiatric or substance abuse disorders |
| 06/05/2008 | US20080132471 Administering a derivative of alendronate or pamidronate and a mucosal membrane protecting agent; osteoporosis, osteopenia, urolithiasis, hypercalcemia, Paget's disease, bone metastasis, multiple myeloma, or neoplastic bone lesion |
| 06/05/2008 | US20080132469 Sh2 domain binding inhibitors |
| 06/05/2008 | US20080132468 Monitoring of Wounds by Measurement of Protease and Protease Inhibitor Levels in Wound Fluids |
| 06/05/2008 | US20080132466 Difructose anhydride and an isoflavone |
| 06/05/2008 | US20080132465 Introducing a serum sample into a separation column having a solid phase; retaining with the solid phase an iron component; removing the iron component from the solid phase |
| 06/05/2008 | US20080132464 Selective induction of apoptosis to treat ocular disease |
| 06/05/2008 | US20080132463 Pharmaceutical use of alpha antigen or alpha antigen gene |
| 06/05/2008 | US20080132462 Administering an agent which inhibits the expression or activity of p46 Shc and/or p52 Shc; determining whether an agent inhibits the phosphorylation of p46 Shc or p52 Shc |
| 06/05/2008 | US20080132461 Introducing RNA which targets the mRNA of the gene for degradation into the cell or organism; maintaining the cell or organism, maintaining the cell or organism under conditions under which degradation of the mRNA occurs |
| 06/05/2008 | US20080132460 Screening for a compound which inhibits p62/ubiquitin binding; detecting the formation of inclusion bodies in neurodegenerative diseases; screening for therapeutic agents that disperse the inclusions |
| 06/05/2008 | US20080132459 Inhibitors of Histone Deacetylase |
| 06/05/2008 | US20080132458 (8S,10S)-10-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione |
| 06/05/2008 | US20080132457 Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| 06/05/2008 | US20080132456 Pharmaceutical Formulation Comprising Low Crystallinity Cellulose |
| 06/05/2008 | US20080132455 Process For Producing Enriched Fractions Containing Up To 100% Of Bacopasaponins From The Plant Materials Of Bacopa Species |
| 06/05/2008 | US20080132449 decorin can dramatically improve the transduction efficiency of gene delivery systems and recombinant adenoviruses expressing decorin can significantly exhibit the potential to penetrate into tumor tissues and anti-tumor effect |
| 06/05/2008 | US20080132447 kit; oligonucleotide; diagnose and treat carnitine deficiency |
| 06/05/2008 | US20080132445 increasing milk production; inhibiting tumors; administering Galanin with prolactin; transgenic mammal |
| 06/05/2008 | US20080132442 biodegradable drug delivery system; fungal infection; inflammation; injection |
| 06/05/2008 | US20080132440 Vitamin D or vitamin C complex with polyglutamic acid; improved stability; food, beverage, cosmetic; esterification |
| 06/05/2008 | US20080131902 Personalized skin care composition and method for production thereof |
| 06/05/2008 | US20080131889 Novel human genes and gene expression products: II |
| 06/05/2008 | US20080131565 Edible composition; partially defatted cocoa solids prepared by heating slaty and/or purple cocoa beans, winnowing the cocoa nibs from the cocoa shells; pressing the cocoa nibs to produce cocoa butter, recovering the cocoa butter and solids; adding the recovered, defatted cocoa solids |
| 06/05/2008 | US20080131535 Skin protection composition |
| 06/05/2008 | US20080131528 Methods and compositions for treating or preventing neurodegenerative diseases |
| 06/05/2008 | US20080131527 Topical analgesic composition |
| 06/05/2008 | US20080131519 Omega-3-polyunsaturated fatty acid ester, in fish oil concentrate containing a 5,8,11,14,17-eicosapentaenic acid ester and a 4,7,10,13,16,19-docosahexaenic acid ester, also lysine of a salt, optionally a zinc salt, or selenium |
| 06/05/2008 | US20080131518 Process for Preparing a Medicament |
| 06/05/2008 | US20080131517 Time-sustained-release formulations comprising a beta-blocker |
| 06/05/2008 | US20080131516 Granule formation |
| 06/05/2008 | US20080131513 Sustained-Release Microspheres and Methods of Making and Using Same |
| 06/05/2008 | US20080131511 Use of(-)-S isomer of 2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane or salt thereof (YM-796) to accelerate tear and salivary fluid secretion without accompanying sweating; sustained release with a hydrophilic base and a polymeric hydrogel as carrier |
| 06/05/2008 | US20080131508 Oral transmucosal nicotine dosage form |
| 06/05/2008 | US20080131507 Pre-blending a drug susceptible to tackiness such as ibuprofen with an additive such as silica; directly compressing the blend without the need for a granulation step or roller compression |
| 06/05/2008 | US20080131503 oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first dosage |
| 06/05/2008 | US20080131501 enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine. |